|Awarded On||August 21, 2019|
|Title||Characterization and optimization of novel allosteric KRAS inhibitors|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Alemayehu Gorfe|
|Cancer Sites||Colorectal, Pancreas, Small Intestine|
*Pending contract negotiation
The National Cancer Institute estimates that there will be 1,735,350 new cases of cancer in 2018 in the US. Activating mutations of a key enzyme in humans, called KRAS, are known to occur in about 20% of all human cancers. Combining these two statistics, we estimate that about 350,000 US residents will be affected by one or another form of KRAS-related cancers per year. Currently, there are no drugs that can directly act on mutated KRAS to stop its cancer-causing activities. As a result, KRAS-related cancers, which include some of the deadliest, such as pancreatic cancer, remain untreatable. Clearly, anti-KRAS medications would save millions of lives. Supported by a previous CPRIT grant, we...